- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | NewcelX Ltd.: NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | 1 | GlobeNewswire (USA) | ||
| 18.09. | NLS Pharmaceutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 18.09. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.07. | NewcelX Ltd.: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | 1 | GlobeNewswire (USA) | ||
| 15.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 515 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 761 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission | 2 | Benzinga.com | ||
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,100 | +2,31 % | Biofrontera mit FDA-Coup: Was Anleger jetzt wissen müssen | ||
| DEFENCE THERAPEUTICS | 0,238 | -2,46 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,334 | -2,45 % | Traws Pharma, Inc. - 8-K, Current Report | ||
| CURIS | 0,338 | -1,46 % | CURIS INC - 8-K, Current Report | ||
| GENPREX | 1,820 | -0,27 % | Genprex highlights preclinical study on TUSC2 gene in brain aging | ||
| TVARDI THERAPEUTICS | 0,830 | -0,60 % | Tvardi auf Chardan Healthcare Conference: Neue Daten nähren Hoffnungen für STAT3-Plattform | ||
| NEOVACS | 0,054 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 2,075 | 0,00 % | Alaunos Therapeutics, Inc. - 8-K, Current Report | ||
| MARKER THERAPEUTICS | 0,705 | -12,42 % | Marker Therapeutics sichert sich FDA-Förderung über 2,6 Millionen US-Dollar für Krebsstudie | ||
| AINOS | 0,808 | -0,02 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,730 | -1,14 % | XFRA 6LJ: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMATINA.BIOPHA. O.N.... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,380 | -2,82 % | Enveric completes drug absorption studies for EB-003 candidate | ||
| NEUPHORIA THERAPEUTICS | 3,370 | 0,00 % | Neuphoria Therapeutics Inc. - 8-K, Current Report | ||
| SCINAI IMMUNOTHERAPEUTICS LTD | 0,540 | -4,36 % | Scinai Immunotherapeutics Ltd.: Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing | Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated... ► Artikel lesen | |
| CLEARMIND MEDICINE | 5,910 | -2,15 % | Clearmind Medicine Inc.: Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -7,41 % bei einem Aktienkurs von 2,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.